Held at the Hospital General Universitario Gregorio Marañón on 14th to 16th November 2018, the 2nd EPIICAL General Assembly welcomed around 50 scientists and healthcare professionals working together to establish new scientific efforts leading to HIV remission in children.
The 3-day meeting gave rise to highly fruitful discussion, at a time when the project has entered a very active phase, with new collaborations ready to start and a closer collaboration with the ViiV research network.
The Assembly acknowledged that EPIICAL is “a tough, large and world mixed project, made of people pulling together research in order to come up with a strategy which ultimately will produce new therapeutic strategies for curing HIV-infected children and new ways of using them”.
We extend a big thank you to Maria Angeles Muñoz-Fernandez, María Dolores García Alonso and José Luis Jimenez from Hospital General Universitario Gregorio Marañón for their warm hospitality and their untiring effort over the course of the event.
We also owe a special thanks to the ViiV HC team for being part of the EPIICAL family in these 3 days of intensive exchange and for their inspiring contributions to the discussion.
Looking forward to meeting you all in Cape Town next year!
Funded by an unrestricted industry grant, EPIICAL aims to implement a predictive platform for the early identification of novel therapeutic strategies for HIV infected children. This involves developing and applying a statistical and mathematical modelling to data derived from cohorts of early treated infants and children to identify virological, immunological and transcriptomic profiles associated with early control of HIV infection after ART initiation as well as viral control following ART interruption.